One-stop procedure combining catheter ablation (CA) and left atrial appendage closure (LAAC) has been a feasible treatment for patients with atrial fibrillation at high risk of stroke and/or bleeding. Although it could achieve considerable rhythm control and stroke prophylaxis, a number of patients has experienced progressive heart failure after the procedure. Notably, previous studies indicate that both pulmonary vein isolation by CA and LAAC could significantly increase left atrial pressure, while currently no study has investigated left atrial pressure change in patients underwent combined procedure. The investigators hypothesise that combined procedure would significantly increase left atrial pressure and subsequently deteriorate cardiac function. Therefore, the investigators aim to measure the left and right atrial pressure change before and after CA and LAAC in combined procedure, and investigate the influence of the pressure change on clinical outcomes.
1. Study aim. This study was designed to measure the left and right atrial pressure change before and after catheter ablation (CA) and left atrial appendage closure (LAAC) combining procedure, and investigate the influence of the pressure change on clinical outcomes. 2. Subject selection. This study is designed to recruit patients diagnosed with atrial fibrillation and planned to undergo combined procedure. Primary inclusion criteria are: i. Atrial fibrillation recorded by 12-lead ECG or Holter that last for longer than 30 seconds within the preceding 6 months; ii. Eligible for left atrial appendage closure, that meet at least one of the followings: 1. At high risk of stroke (CHA2DS2-VASc score≥3 in female, ≥2 in male) and/or bleeding (HAS-BLED score≥3); 2. Contraindicated to oral anticoagulation (OAC); 3. Refused OAC treatment albeit comprehensively informed of the necessity and benefits of OAC treatment. 3. Procedure detail. All the patients recruited is planned to undergo combined procedure. CA is performed before LAAC. For CA, the energy source is optional (either radiofrequency or cryoenergy). And ablation should be performed for pulmonary vein isolation only. For LAAC, the occluder type is optional (either plug or pacifier occluder), and intracardiac echocardiography or transesophageal echocardiography (TEE) is optional. For atrial pressure measurement, right atrial pressure should be measured before transseptal puncture and after combined procedure is accomplished. Left atrial pressure should be measured at 3 timepoints: after transseptal puncture, after pulmonary vein isolation and after LAAC. Atrial pressure is measured via Swartz transseptal puncture sheath. And at each timepoint, atrial pressure should be recorded at 1min, 3min, and 5min after the placement of the sheath. 4. Follow-up. study endpoint includes a primary composite endpoint of rehospitalization due to heart failure and death due to cardiovascular disease, and secondary endpoints including: 1. all-cause mortality 2. major cardiovascular adverse event 3. rehospitalization due to cardiovascular diseases 4. recurrence of atrial arrhythmia 5. stoke/transient ischemic attack 6. echocardiographic measurement 7. quality of life evaluation 8. cardiac function evaluation 9. evaluation of left atrial appendage closure. Patients are required to have outpatient follow-up at 3rd month, 12th month, and every year since then. The anti-thromboembolic regimen should follow: 3-month OAC treatment and 3-month double anti-platelet therapy and lifelong single anti-platelet therapy. For LAAC follow-up, either TEE or CTA is scheduled to perform in the 3rd month after procedure.
Study Type
OBSERVATIONAL
Enrollment
100
both left and right atrial pressure was measured using transseptal puncture sheath before and after combined procedure
Department of Cardiology, Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGComposite endpoint
Rehospitalization due to heart failure and death due to cardiovascular disease
Time frame: From date of inclusion until the date of first documented rehospitalization due to heart failure or date of death due to cardiovascular disease, whichever came first, assessed up to 60 months
All-cause mortality
death of any reason
Time frame: From date of inclusion until the date of documented death of any reason, assessed up to 60 months
Major cardiovascular adverse event
cardiovascular events including myocardial infarction, malignant arrhythmia, acute heart failure, cardiac tamponade.
Time frame: From date of inclusion until the date of first documented cardiovascular events mentioned above, assessed up to 60 months
Rehospitalization due to cardiovascular diseases
Rehospitalization due to any cardiovascular diseases
Time frame: From date of inclusion until the date of first documented rehospitalization due to cardiovascular diseases, assessed up to 60 months
Early recurrence of atrial arrhythmia
Atrial tachycardia, atrial flutter, or atrial fibrillation that last for longer than 15 seconds recorded by ECG or Holter
Time frame: From time of completion of combined procedure until the third month since the procedure
Recurrence of atrial arrhythmia
Atrial tachycardia, atrial flutter, or atrial fibrillation that last for longer than 15 seconds recorded by ECG or Holter
Time frame: From the third month since the procedure until the date of recurrence of atrial arrhythmia as described above, assessed up to 60 months
Stoke/transient ischemic attack
Cerebral infarction, intracranial hemorrhage, or transient ischemic attack confirmed by CT/MRI
Time frame: From date of inclusion until the date of first documented stoke/transient ischemic attack, assessed up to 60 months
Change from baseline echocardiographic measurement at 3 months
Echocardiographic measured left atrial parameters including left atrial volume, left atrial volume index, e, e' and left ventricle parameters including left ventricular ejection fraction, left ventricle systolic and diastolic diameter.
Time frame: 3 months after combined procedure
Change from baseline echocardiographic measurement at 1 year
Echocardiographic measured left atrial parameters including left atrial volume, left atrial volume index, e, e' and left ventricle parameters including left ventricular ejection fraction, left ventricle systolic and diastolic diameter.
Time frame: 1 year after combined procedure
Change from baseline echocardiographic measurement at 5 years
Echocardiographic measured left atrial parameters including left atrial volume, left atrial volume index, e, e' and left ventricle parameters including left ventricular ejection fraction, left ventricle systolic and diastolic diameter.
Time frame: 5 years after combined procedure
Change from baseline quality of life evaluation at 3 months
EQ-5D questionnaire evaluation of quality of life
Time frame: 3 months after combined procedure
Change from baseline quality of life evaluation at 1 year
EQ-5D questionnaire evaluation of quality of life
Time frame: 1 year after combined procedure
Change from baseline quality of life evaluation at 5 years
EQ-5D questionnaire evaluation of quality of life
Time frame: 5 years after combined procedure
Change from baseline walking distance of 6-min walk test at 3 months
Maximum walking distance measured from 6-min walk test
Time frame: 3 months after combined procedure
Change from baseline walking distance of 6-min walk test at 1 year
Maximum walking distance measured from 6-min walk test
Time frame: 1 year after combined procedure
Change from baseline walking distance of 6-min walk test at 5 years
Maximum walking distance measured from 6-min walk test
Time frame: 5 years after combined procedure
Evaluation of left atrial appendage closure at 3 months
Either transesophageal echocardiography or CTA evaluation of occluder position, residual flow, presence of thrombosis.
Time frame: 3 months after combined procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.